EMA
approval
· 2026-03-05
EMA Authorised: VacPertagen (recombinant pertussis toxin;filamentous haemagglutinin) — BioNet Europe
Summary
The EMA authorised VacPertagen, a pertussis vaccine containing recombinant pertussis toxin and filamentous haemagglutinin, for protection against pertussis (who…
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Status: Authorised. Therapeutic area: Whooping Cough;Infections. MAH: BioNet Europe. Decision date: 05/03/2026